论文部分内容阅读
目的探讨前列地尔联合贝那普利治疗糖尿病肾病蛋白尿的临床效果。方法选取2012年8月至2016年8月期间收治的糖尿病肾病蛋白尿患者82例,随机分为两组。对照组(n=41)采用贝那普利治疗,观察组(n=41)采用贝那普利联合前列地尔治疗,持续给药20 d,通过治疗有效率、尿蛋白、微白蛋白排泄率、不良反应发生率等指标评估临床疗效。结果观察组治疗总有效率92.68%,高于对照组的70.73%,差异有统计学意义(P<0.05);治疗后,观察组患者24 h尿蛋白水平、24 h尿微白蛋白排泄率均低于对照组,差异有统计学意义(P<0.05);观察组和对照组不良反应发生率分别为9.76%和14.63%,差异无统计学意义(P>0.05)。结论针对糖尿病肾病蛋白尿患者,前列地尔联合贝那普利治疗,有利于缓解临床症状,降低24 h尿蛋白水平,不良反应少,安全性较高。
Objective To investigate the clinical efficacy of alprostadil combined with benazepril in the treatment of diabetic nephropathy proteinuria. Methods Eighty-two patients with diabetic nephropathy albuminuria from August 2012 to August 2016 were randomly divided into two groups. The control group (n = 41) was treated with benazepril. The observation group (n = 41) was treated with benazepril combined with alprostadil for 20 days. The treatment efficiency, urine protein and microalbumin excretion Rate, the incidence of adverse reactions and other indicators to assess the clinical efficacy. Results The total effective rate of observation group was 92.68%, which was higher than that of control group (70.73%), the difference was statistically significant (P <0.05). After treatment, 24 h urinary protein level and 24 h urine microalbumin excretion rate The difference was statistically significant (P <0.05). The incidence of adverse reactions in the observation group and the control group were 9.76% and 14.63% respectively, with no significant difference (P> 0.05). Conclusion For patients with diabetic nephropathy and proteinuria, alprostadil combined with benazepril treatment is beneficial to relieve clinical symptoms and reduce 24-hour urinary protein levels, with fewer adverse reactions and higher safety.